Group B streptococcal infection is a major cause of neonatal mortality. Antibody to the capsular polysaccharide protects against invasive neonatal disease, but immunization with capsular polysaccharides fails to elicit protective antibody in many recipients. Conjugation of the polysaccharide to tetanus toxoid has been shown to increase immune response to the polysaccharide. In animal models, C proteins of group B streptococci are also protective determinants. We examined the ability of the beta C protein to serve in the dual role of carrier for the polysaccharide and protective immunogen. Type m polysaccharide was covalently coupled to beta C protein by reductive amination. Immunization of rabbits with the polysaccharideprotein conjugate elicited high titers of antibody to both components, and the serum induced opsonophagocytic killing of type m, Ia/C, and lb/C strains of group B streptococci. Female mice were immunize with the conjugate vaccine and then bred; 93% of neonatal pups born to these dams vaccinated with conjugate survived type m group B streptococcal challenge and 76% survived type Ia/C challenge, compared with 3% and 8% survival, respectively, in controls (P < 0.001). The beta C protein acted as an effective carrier for the type m polysaccharide while simultaneously inducing protective immunity against beta C protein-containing strains of group B streptococci. (J. Cl InvesL 1994. 94:286-292.)
Introduction
Recent epidemiologic data confirm that group B streptococci (GBS)' remain the leading cause of serious neonatal infection (1) . The rates of mortality and severe neurologic sequelae that result from this pathogen are unacceptably high, despite continued sensitivity to antibiotics and improved recognition and therapy. Each year in the U.S., several thousand infants become seriously infected with this pathogen, and it is estimated that 15% succumb. In addition, the importance of GBS infections in adults has increasingly been recognized; cases in adults now account for fully half of invasive GBS disease. Immunization has been proposed as a strategy for the prevention of GBS infection (2) . The capsular polysaccharides of the most prevalent serotypes causing disease have been the most widely explored antigens for this purpose (3, 4) . While the polysaccharides alone are not sufficiently immunogenic to elicit protective antibodies in some recipients, glycoconjugate vaccines with the type-specific polysaccharides covalently linked to tetanus toxoid (TT) have shown high rates of protective immunization in experimental animals (5) (6) (7) (8) (9) (10) . Human trials of vaccines based on capsular polysaccharide-TT conjugates are now under way. Four capsular polysaccharides (serotypes Ia, Ib, II, and III) currently predominate among GBS strains causing invasive disease. Therefore, to be highly-effective, this type of GBS vaccine will need to be multivalent, containing each of the prevalent capsular serotypes. The widespread use of TT as both a vaccine and a carrier protein in conjugate vaccines may have drawbacks, including uncomfortable local reactions to immunization and suppression of responses to the hapten ( 1 1, 12) . Thus, we wish to explore the use of alternative carrier proteins, which themselves may elicit protective immunity to GBS.
C proteins are surface-expressed antigens of GBS that also elicit protective immunity in experimental animals (13, 14) . Although the alpha and beta C proteins are rarely found in type III strains of GBS, one or both of these antigens are expressed in most strains of other serotypes ( 15, 16) . We and others have shown that both alpha and beta C proteins are protective antigens for GBS in experimental animals (17) (18) (19) . In addition to its capacity to elicit protective antibody, the beta C protein is known to bind human IgA to the surface of GBS (20, 21) . Active immunization with the beta C protein in female mice protects their offspring from lethal infection with strains that express this antigen (22) . A 
Baylor College of Medicine (generously provided by Dr. Carol J. Baker, Baylor College of Medicine, Houston, TX) and have been previously described (16) . The serotypes of these strains are shown in Table I . Beta C protein. The beta C protein was generously provided by Dr. Milan Blake (Rockefeller University, New York) and was produced by extraction into SDS from serotype Ib/C GBS strain H36B5, purified by gel filtration chromatography as described previously (20) . Purity was assessed by observation of a single 130-kD band on silver-stained SDSpolyacrylamide gel.
Oxidation of GBS type III polysaccharide. Type Iml GBS capsular polysaccharide (< 200,000 Mr) was purified from GBS strain M781 as previously described (5) . Aldehydes were formed on GBS type III polysaccharide by the conversion of a portion of the side chain sialic acid residues by limited oxidation with use of sodium periodate as described previously (5, 23) . Briefly, 8.1 mg of purified GBS type III polysaccharide, possessing -8 /Lmoles of sialic acid, was combined with 2 IHmoles of freshly prepared sodium m-periodate (Sigma Chemical Co., St. Louis, MO) in a total volume of 0.5 ml of water. The mixture was incubated at room temperature for 90 min in the dark. After incubation, excess periodate was consumed by the addition of ethylene glycol. Confirmation of the extent of oxidation was obtained by gas chromatography-mass spectrometry (GC-MS) of trimethylsilyl derivatives (5). The mixture was placed in dialysis tubing (Spectropor #1; Spectrum Medical Industries, Inc., Los Angeles, CA) and dialyzed at 40C against a total of 8 liters of water. The dialyzed sample was filtered (0.45 pm) and dried by lyophilization.
Conjugation of GBS type III polysaccharide to GBS beta C protein.
oxidized type III polysaccharide (5.5 mg) was combined with 5 mg of beta C protein in a total volume of 0.5 ml of phosphate buffered saline, pH 9.0-9.5. Sodium cyanoborohydride (33 mg) was added and the mixture incubated at room temperature in the dark. To insure complete coupling an additional 12 mg of sodium cyanoborohydride was added to the mixture after 6 d of incubation. The pH of the reaction was monitored by spotting a 2-,ul aliquot onto pH paper and maintained at 9.0-9.5 by the addition of 0.1 N NaOH. Conjugation failed to occur when the pH was not maintained above 8.0. The progress of the conjugation was monitored by gel filtration chromatography of samples as described previously (9 ELISA. Antibodies to the type HI GBS polysaccharide and to the beta C protein were measured by ELISA as described previously (5, 22) . The titers were determined by serial twofold dilution (from a starting dilution of 1:3,200) as the greatest dilution with A405 -0.2 after 30 min of development.
ELISA inhibition. Relative binding affinities of antibodies to beta C protein in sera prepared to purified beta C protein, either alone or as part of the conjugate vaccine, were assessed by inhibition of ELISA reactivity. Purified beta C protein at concentrations ranging from 5 to 5,000 ng/ml was used to inhibit the binding of the antisera (anti-beta C protein diluted 1:400,000 and anti-HI-/ diluted 1:200,000 to achieve similar ELISA reactivity) to plates coated with purified beta antigen.
The absorbance values were plotted against log10 of beta C protein concentration to generate inhibition curves.
Similarity of epitope expression of purified protein either alone or as part of a conjugate vaccine was assessed by determining their relative abilities to compete with the beta C protein expressed on intact GBS for binding to antiserum raised to the beta C protein. ELISA plates were coated with type Ib/C GBS strain 7357b as previously described (22) . ELISA was performed with antiserum to the purified protein (diluted 1:100,000) incubated with either the III-,8 conjugate or the beta C protein ranging in protein concentration from 0.05 to 5 ug/ml.
Relative binding affinities of the beta C protein and the III-0 conjugate for human IgA, was measured by inhibition of binding of IgA1 to ELISA plates coated with beta C protein as follows: III-13 conjugate and unconjugated beta C protein were serially diluted twofold from a starting protein concentration of 2.0 ug/ml and preincubated with an equal volume of human myeloma IgA, (1.0 Itg in 50 ul) for 2 h at room temperature. The mixture (100 /A) was transferred to ELISA plates coated with beta C protein (200 ng/well) and incubated at room temperature for 1 h. After washing, goat anti-human IgA conjugated to alkaline phosphatase (Tago, Inc., Burlingame, CA), diluted 1:1000, was added to the ELISA wells and incubated at 37°C for 1 h.
The plates were washed and developed with commercial substrate (Sigma Chemical Co.). Percentage inhibition was calculated as [(A405 without inhibitor-A,40 with inhibitor)/A405 without inhibitor] X 100.
The point of 50% inhibition was determined graphically. Opsonophagocytic assay. The functional capacity of antibodies to C proteins of GBS was assessed by an opsonophagocytic assay (24) measuring in vitro killing of GBS. In brief, a 300-jl volume of human polymorphonuclear leukocytes (-3 X 106 cells) was mixed with the test GBS strain (-1.5 x 106 CFU), 50 p1 of human serum (prepared for use as a complement source by absorption on ice for 30 min with GBS of homologous serotype), and 100 p1 of antibody diluted 1:100. Pooled rabbit antisera to GBS type-specific polysaccharides conjugated to TT were used as the reference sera (5, 8, 10) . ELISA titers of these antisera to the homologous polysaccharides were as follows: Ia: 200,000; Ib: 100,000; 1: 100,000, III: 64,000. Viable GBS cells were enumerated as 10-fold dilutions on blood agar plates immediately and after a 60-min incubation at 370C, and the difference was calculated as killing. The assay was repeated in the absence of antibody. The result is reported as the "log kill," which is the difference between killing with and without antibody for at least two determinations per strain.
Neonatal (Fig. 1) . The protein-polysaccharide conjugate had a higher M, than the unconjugated protein, barely entering the running gel. In the ELISA inhibition experiments (Fig. 2) , 50% inhibition of IgAl binding occurred at a concentration of 3 jsg/ml of uncoupled beta C protein and > 90% inhibition occurred at 25 ug/ml, whereas less than 60% inhibition of IgA binding could be achieved by the conjugate at 200 jig/ml ( =100 ,ig/ml beta C protein), the highest concentration tested.
Opsonophagocytosis of GBS strains by serum raised to the III-13 vaccine. Antiserum raised to the I1-1 conjugate vaccine induced killing by human polymorphonuclear leukocytes (PMNs) in the opsonophagocytic assay against strains expressing either the beta C protein or the type HI capsular polysaccharide (Table III) . The log reduction in CFU (minus the log reduction in CFU in the absence of antiserum) was comparable to that induced by antiserum raised to the I1-TT vaccine. Strains that expressed neither the type III capsular polysaccharide nor the beta C protein (i.e., 515 serotype Ia/C alpha+ beta-, and 18RS21 serotype II) were not rendered susceptible to phagocytic killing by the 111-1 conjugate vaccine-induced antiserum. One strain, S42 was previously reported to be beta C protein negative ( 16) but exhibited a high level of opsonophagocytic killing with the anti-Im-,8 serum. On reexamination of the strain S42 with monoclonal antibody to beta (3E7) by western blot, this strain was found, in fact, to express low levels of the beta C protein.
Neonatal mouse protection by immunization with III-# vaccine. Active immunization with III-,1 vaccine greatly enhanced survival of mice challenged either with type Ia/C (alpha+, beta+) strain A909 or with type III strain M781 (Table IV) : 93% of neonatal pups whose mothers were immunized with the 11-13 vaccine survived intraperitoneal challenge with type III GBS compared with 4% of those whose mothers were immunized with the beta C protein alone (P < 0.001) and 83% of those whose mothers were immunized with Il-lT (NS); 76% of neonatal mice whose mothers were immunized with the III-,1 vaccine survived challenge with the Ia/C strain of GBS compared with 3% of those whose mothers were immunized with H1-TT (P < 0.001) and 62% of those whose mothers were immunized with beta C protein alone (NS). While there was improved survival among the neonates of dams who received alum as an adjuvant with the vaccine, it was not statistically significant. Survival rates between litters within a test group were similar and each litter within a test group showed statistically significant increase in survival compared with the heterologous control (P < 0.02) . Hib polysaccharide in a Hib-TT conjugate (12) . Repeated immunization with the same carrier protein may result in uncomfortable local reactions, thereby diminishing the palatability and perhaps the acceptance of these vaccines.
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In the case of GBS, at least four capsular polysaccharides (serotypes Ia, Ib, II, and III) currently predominate among GBS strains causing invasive disease, therefore, a polysaccharide based GBS vaccine will need to be multivalent containing each of the prevalent capsular serotypes. In such a multivalent vaccine, the quantity of TI required as a carrier may exceed the allowable amount for routine immunizations. Also, the widespread use of TT as both a vaccine and a carrier protein in this and other polysaccharide-protein conjugate vaccines may have drawbacks, including uncomfortable local reactions to immunization and suppression of responses to the hapten ( 11, 12) .
In contrast, the use of a protective antigen from the target organism may enhance the effectiveness of a conjugate vaccine by eliciting antibodies that are themselves protective. The pro- Most vaccines currently under study for the prevention of GBS infection are based on the capsular polysaccharide antigens (5, 7, 8, 10, 30) . The most prevalent type-specific polysaccharides are well characterized and have been shown to be critical targets for specific immunity in preventing neonatal GBS infection (3, 4, 31 ) . These antigens have been safely used to immunize pregnant women, and type-specific antibody has been shown to cross the placenta at levels protective to newborns (4) . Although the polysaccharides are themselves not adequately immunogenic in some recipients, conjugate vaccines composed of type-specific polysaccharide conjugated to tetanus toxoid have been shown to elicit protective antibodies in animals and are currently in human trials (5, 8) .
In addition to the capsular polysaccharides, GBS possess protective surface protein antigens including the C proteins alpha and beta present mainly in non-type mII strains (15, 16) , the Rib protein present mainly in strains of capsular serotypes II and HI (32), and the R proteins found in several capsular types (33, 34) . We have chosen to study one of these surface proteins for its use as both carrier and immunogen in a conjugate vaccine. The beta C protein elicits maternal antibodies that protect neonatal mice from lethal challenge with GBS which express the beta C protein (22) . We now demonstrate that the beta C protein can be covalently coupled to the type I1 GBS polysaccharide through limited oxidation of polysaccharide sialic acid residues followed by reductive amination. Conjugation by this method which is thought to occur mainly at lysine residues of the protein component (35) , may have been facilitated by the extremely lysine-rich nature of the beta C protein, which has 156 lysine residues out of 1,134 amino acids (36, 37) . Conjugation of these two molecules required careful titration of pH because of the highly acidic nature of both the beta C protein and the type III polysaccharide (36, 37) .
Immunization of rabbits with the I11-1 conjugate vaccine elicited high antibody titers against the type HI polysaccharide, whereas the type HI polysaccharide alone has been shown to be nonimmunogenic in rabbits (5) . Thus, the beta C protein functions as an effective carrier protein in this vaccine presumably by allowing the development of T cell-dependent immunity to the polysaccharide. The conjugate vaccine also elicited antibodies to beta C protein at titers comparable with those elicited by the beta C protein alone (22) . Conjugate vaccineinduced beta C protein antibodies reacted with the beta C protein (38) showed that some parturient women colonized with GBS possess naturally occurring antibody to the beta C protein and that there was concordance between ELISA titers of antibody in these women and their neonates suggesting transplacental passage of beta-specific antibody in humans. The beta C protein binds specifically to human IgA via a nonimmune mechanism (20) . One theoretical drawback to the use of the beta C protein in a conjugate vaccine is the ability of the vaccine to bind to human IgA. The consequences of this binding are not clear, and there are no unusual immune phenomena associated with infection with GBS strains that express these proteins (or other bacteria that express immunoglobulin binding proteins). Conjugation to the polysaccharide appeared to diminish greatly the affinity of the protein for IgA binding. However, the immunoblot of the conjugate to human IgA demonstrated some detectable binding, even after conjugation. The diminution of binding may occur via steric interference with the IgA binding site, through partial denaturation of the protein, or by binding to lysine residues in or adjacent to the active site. It may be possible to eliminate this theoretical concern associated with use of the beta C protein by fully eliminating IgA binding through alteration of the nature of the conjugation, for example, by increasing the percentage of sialic acid residues that are oxidized and thus increasing the degree of cross-linking in the glycoconjugate. Alternatively, the beta C protein could be modified, for example, by mutagenesis, to eliminate IgA binding. Finally non-IgA binding variants of the beta C protein have been described that, if fully immunogenic and protective, may represent alternative carrier proteins (39) . Despite this alteration in functional activity, conjugation did not appear to alter antigenic or immunogenic properties of the protein.
The beta C protein is found in -40% of non-type m GBS clinical isolates (15) . The 
